🔎 Trials Near Me

Akèy › Kansè nan tete › Vermont › Burlington

Etid klinik pou Kansè nan tete nan Burlington, VT

5 etid pou Kansè nan tete ap chèche patisipan nan sit nan ak bò kote Burlington (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Ap rekriteFaz 3
  • The University of Vermont Medical Center Inc., Burlington
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07174336

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

Ap rekriteFaz 2
  • The University of Vermont Medical Center Inc., Burlington
Laj 18 ak plis · Fanm · Mizajou Sep 22, 2026 · NCT07287098

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Ap rekriteFaz 3
  • University of Vermont Medical Center, Burlington
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06492616

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Ap rekriteFaz 3
  • University of Vermont Medical Center, Burlington
  • University of Vermont and State Agricultural College, Burlington
Laj 18 a 60 · Fanm · Mizajou Sep 2, 2026 · NCT05879926

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Ap rekriteFaz 3
  • University of Vermont Medical Center, Burlington
  • University of Vermont and State Agricultural College, Burlington
Laj 50 a 70 · Tout sèks · Mizajou Apr 23, 2026 · NCT04852887

Etid Kansè nan tete nan lòt vil

Lòt etid nan Burlington

Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.